A new drug called “the saliva drug” has been discovered that’s supposed to treat depression

The New York Times reports that the pharmaceutical company Theranos has been working on an artificial immune system to fight infections in the body, and the drug company says it’s working on the same thing with the saliva drug. 

The drug, called “Lys-Ateza” (or “Ate-za”), was first reported in The New England Journal of Medicine in October of last year.

It was originally developed by Theranos and is based on an enzyme that is part of the body’s immune system. 

It’s a non-invasive way to treat infections and allergies that may be caused by viruses, bacteria, and protozoa. 

“There are many examples of non-pharmacological interventions that are working on a host of diseases and disorders, including diabetes, cancer, cardiovascular disease, Alzheimer’s disease, and many others,” said Dr. David W. Levine, director of the National Institute on Aging and senior vice president of the company. 

Theranos says that the new drug is “effective against HIV-1 and HIV-2, but is not as effective against influenza and tuberculosis.” 

The company has been making progress in this area, but the FDA is still looking into the safety and efficacy of this new medication. 

LysAteZA has been tested on people, and Theranos says it will soon begin testing on animals.

Theranos is working on testing in other animals and says it hopes to have a drug ready for clinical testing by 2019.

The company has also raised money to develop and manufacture the drug, and is looking to raise $2 billion to do so. 

We’re excited to see that the drug is getting more people to the front lines and is being tested on millions of people who are not just in the U.S., but around the world. 

As a part of this effort, Theranos will continue to partner with universities and research centers to study and improve the drug’s efficacy and safety.

Drug found in bath salts is bath salts, police say

A federal agent said Saturday that federal authorities found a drug called bath salts in a bathtub that had been used to make ecstasy.

The DEA said in a statement that agents arrested a man on Saturday and seized two packets of the drug, which was seized during a search of a suburban Denver apartment.

Bath salts were sold online as a way to boost your mood, but the DEA says it can also have severe effects.

The drug can cause hallucinations, delusions and even death.

It’s the latest in a string of seizures of the psychoactive drug that the DEA said it seized in January.

Authorities have seized dozens of bath salts and other substances in recent weeks, including several pounds of methamphetamine, according to DEA data.

A person can take bath salts to make themselves feel better, but it can lead to hallucinations and a rapid rise in the amount of the substance in the body, according the DEA.

What are some of the latest malaria drugs?

The Drug Enforcement Administration (DEA) has released a list of a few malaria drugs that the agency is now monitoring.

The list, which was released by the DEA, includes two new malaria drugs.

The first is a drug called Malaria B, which has been on the market since 2013 and is a non-psychoactive formulation of the drug malaria b, according to the agency.

It was first approved by the FDA in 2018, and its active ingredient is a form of malaria toxin, the agency said.

It is currently on the markets of a number of countries including China, India, Vietnam, Nigeria, and South Africa.

The second new malaria drug, Malaria C, is currently in the investigational stage, according the DEA.

It contains the same active ingredient as the first drug but it has been shown to have fewer side effects, according Toomey.

It can be administered as a shot, a pill, or a tablet, the DEA said.

Malaria A, also known as malaria b, is a newer malaria drug that has been approved by two different countries, India and South Korea.

The drug was approved by both countries in 2019 and was shown to be less toxic and less likely to cause severe side effects than the drug that the FDA approved in 2018.

The DEA said Malaria H, which is currently undergoing testing in the U.S., is an investigational drug that is currently being evaluated for safety and efficacy.

MalaB has been developed by Pfizer, which makes the drug.

The agency said the drug was evaluated for efficacy against malaria in humans and has not yet been approved for sale in the United States.

In the meantime, the U,S.

has seen more cases of malaria.

Between January and July this year, there were 6,938 cases of the disease in the US, according Dr. Andrew D. Schlosser, the assistant secretary for public affairs and emergency preparedness at the DEA who said the numbers are expected to climb further.

He said the U.,S.

reported more than 1,500 new malaria cases in August, which the agency attributed to an increase in the number of new cases of infection due to the global pandemic.

More than 5,000 Americans died from malaria in the first five months of 2017, according data from the Centers for Disease Control and Prevention (CDC).